AD
Adaptive Biotechnologies Corporation
ADPT · NASDAQ
$29.43 -1.77% (-$0.53)
1M +11.31%
Market Cap $4.46B
P/E Ratio -
Div. Yield -
ROE 32.64%
Analiza
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Piotroski F-Score Moderate
4/9Valuation
0 /100
Expensive P/B 31.20x
P/S 14.47x
EV/FFO N/A
Growth
66 /100
Stable Book val. growth 22.17%
Rev. growth 14.34%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 12.16%
Gross margin 75.44%
FCF margin 7.80%
Quality
6 /100
Poor ROA 9.97%
ROIC 6.67%
Asset turnover 0.48x
Debt
23 /100
High Int. coverage -2.79x
Debt/Equity 2.87x
Current ratio 4.79x
Stability
14 /100
Unstable EPS volatility 61.91%
Beta 2.10x
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o ADPT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Chad Robins
Employees
624
Headquarters
Seattle
Prihajajoči dogodki
04 NOV.
Earnings
Upcoming earnings report